Background Changes in body fat distribution are an adverse effect of therapy with HIV
protease inhibitors (PI). It has been suggested that nucleoside analogue reverse …

Background Lipoatrophy and/or central fat gain are observed frequently in patients on
antiretroviral therapy (ART). Both are assumed to be antiretroviral adverse drug reactions …

Background Risk factors for lipodystrophy in patients infected with HIV-1 treated with highly
active antiretroviral therapy (HAART) containing HIV-1 protease inhibitors are poorly …

Objective: To compare body composition, body fat distribution and insulin secretion in
patients taking nucleoside reverse transcriptase inhibitor (NRTI) therapy. Design and setting …

Mortality rates in the HIV-infected patient population have decreased with the advent of
highly active antiretroviral therapy (HAART) for the treatment of AIDS. Due to the chronic …

Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Background Progressive subcutaneous fat wasting, fat accumulation, dyslipidaemia and
insulin resistance in HIV-infected patients on antiretroviral therapy has been attributed to the …

A syndrome combining peripheral fat wasting (affecting facial fat pads, arms and legs),
insulin resistance and hyperlipidaemia has been identified in HIV-infected patients treated …

The effective use of potent antiretroviral therapy has dramatically improved the life
expectancy for HIV‐infected individuals. Long‐term complications of both HIV‐infection and …

Lipoatrophy is perhaps the most visibly recognisable component of antiretroviral-therapy-
associated lipodystrophy due to the rarity of this form of body composition change in the …